Brand Index Methodology
The Morning Consult Brand Index is an indicator of brand strength among consumers. Each Fortune 500 company receives a score based on a ratio of favorable to unfavorable impressions among U.S. adults and its overall favorability. This ensures that a score takes into account how well-liked a company is among people who have an opinion of it without penalizing companies that are not consumer-facing.
Morning Consult polls thousands of adults across the country each week. The surveys are conducted online using large, established online survey vendors. The data is weighted to approximate a nationally representative sample based on age, race/ethnicity, gender, educational attainment, region, annual household income, home ownership status and marital status.
The pharmaceutical giant raked in $40.1 billion in global sales in 2017, an increase of 1% from the year before. Merck’s superstar cancer immunotherapy drug Keytruda has continued to be the big performer; it alone brought in $1.46 billion in the first quarter of this year–an increase of 150% from the same time period last year. Success has been a mixed blessing, however. Keytruda now plays an outsize role in Merck’s portfolio, responsible for about 15% of the company’s sales. Moreover, plans to expand the drug’s applications have hit a snag: A collaboration with the biotech research firm Incyte to combine the drug with another experimental therapy has been recently halted.
CEO
Kenneth C. Frazier
CEO Title
Chairman, President & Chief Executive Officer
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Kenilworth, N.J.
Website
Years on Fortune 500 List
24
Employees
69,000
SPONSOR CENTER
| $ millions | % change | |
|---|---|---|
| Revenues ($M) | $40,122 | 0.8% |
| Profits ($M) | $2,394.0 | -38.9% |
| Assets ($M) | $87,872 | |
| Total Stockholder Equity ($M) | $34,336 | |
| Market Value — as of March 29, 2018 ($M) | $146,862 |
| Profit as % of Revenues | 6.0% | |
| Profits as % of Assets | 2.7% | |
| Profits as % of Stockholder Equity | 7.0% |
| Earnings Per Share ($) | 0.87 | |
| EPS % Change (from 2016) | -38.3% | |
| EPS % Change (5 year annual rate) | -15.3% | |
| EPS % Change (10 year annual rate) | -5.2% |
| Total Return to Investors (2017) | -1.5% | |
| Total Return to Investors (5 year, annualized) | 10.1% | |
| Total Return to Investors (10 year, annualized) | 3.5% |
- Previous Close:
- Market Cap: NaNB
- Next Earnings Date:
- High:
- Low:
- 52 Week High:
- 52 Week Low:
- 52 Week Change %: 0.00
- P/E Ratio: n/a
- EPS:
- Dividend Yield: n/a
News about Merck
Trump is pleased with the result of his blast.
GSK's new shingles vaccine Shingrix is in short supply in the U.S.
CEOs' decisions have the power to change society—not just stock prices.
The story of Alzheimer's drug development is one of perpetual tragedy and setbacks.
The alliance of nearly 500 chief executives reports a successful first year in addressing inclusion at their firms and has big goals ahead.
Quotes delayed at least 15 minutes. Market data provided by Interactive Data. ETF and Mutual Fund data provided by Morningstar, Inc.. Dow Jones Terms & Conditions: http://www.djindexes.com/mdsidx/html/tandc/indexestandcs.html. S&P Index data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions